Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.36 |
| ▸ | DNM2 | P50570 | 7/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21509894 | 0.97 | GPR84 (0.38) | GPR84DNM2NR1I2HTTKDM4E | |
| SCHEMBL25898714 | 0.93 | GPR84 (0.32) | GPR84MAPTTLR8 | |
| SCHEMBL19772965 | 0.90 | NR1I2 (0.37) | GPR84DNM2NR1I2HTTKDM4E | |
| SCHEMBL21509731 | 0.90 | GPR84 (0.33) | GPR84DNM2MEN1MAPTKMT2A | |
| SCHEMBL21711086 | 0.74 | MAPT (0.33) | HTTKDM4EALDH1A1MAPT | |
| SCHEMBL19772930 | 0.73 | PPARG (0.33) | GPR84NR1I2KMT2A | |
| SCHEMBL23869472 | 0.72 | GPR84 (0.35) | GPR84DNM2NR1I2KDM4EHPGD | |
| SCHEMBL25632884 | 0.71 | NR1I2 (0.36) | NR1I2HTTMEN1KMT2A | |
| SCHEMBL23869345 | 0.71 | NR1I2 (0.36) | NR1I2HTTMEN1KMT2A | |
| SCHEMBL25015841 | 0.71 | KDM4E (0.37) | GPR84NR1I2HTTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | TYK2, PDXK, JAK1 | GPR84 3102/4885DNM2 2017/4885NR1I2 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.